Oncology remains a leading source of scientific innovation and biopharma growth, but translating innovation into durable commercial value is becoming increasingly complex. Precision medicine, advanced treatment modalities, pricing reform, loss of exclusivity, and evolving care networks are reshaping how therapies are developed, positioned, accessed, and delivered.

This eBook brings together IQVIA’s Brave New World: Oncology Deep Dive series to examine the scientific, competitive, economic, and care-delivery forces shaping the next phase of the U.S. oncology market. Across seven chapters, IQVIA experts explore how organizations can navigate increasingly precise patient populations, evolving treatment pathways, compressed value horizons, and a more interconnected care ecosystem.

Download this eBook to learn:

• Why precision oncology is making patient identification, biomarker testing, and diagnostic execution increasingly critical to commercial success
• How evolving treatment pathways in breast cancer, NSCLC, and multiple myeloma are changing the role of positioning, evidence, and sequencing
• How CAR-T therapies and bispecific antibodies are reshaping treatment decisions around access, delivery, patient eligibility, and site of care
• Why increasing competition and convergence across oncology are making differentiation beyond clinical performance more important
• How Inflation Reduction Act pricing provisions and loss of exclusivity are compressing oncology’s value horizon and changing lifecycle strategy
• Why oncology care networks and consolidation are reshaping patient flow, treatment access, and where adoption decisions are made
• How earlier coordination across portfolio strategy, evidence, access, delivery, and lifecycle planning can help translate scientific innovation into durable commercial value